British Columbia Cancer Agency/University of British Columbia-Vancouver Cancer Centre, Division of Medical Oncology, 600 West 10th Avenue, Vancouver, BC V5Z4E6, Canada.

This email address is being protected from spam bots, you need Javascript enabled to view it

Patients with metastatic testicular cancer exhibit an excellent prognosis. However, the outcome for patients with relapse after cisplatin-based chemotherapy remains unsatisfactory. Several larger studies have been recently published.

Objective: To review the treatment of patients with testicular cancer after failure of first-line chemotherapy.

A literature search was performed for studies investigating therapies for relapsed testicular cancer.

The prognosis of patients relapsing after first-line cisplatin-based chemotherapy has improved with multimodality therapy, including conventional and high-dose chemotherapy, surgery and radiation. Prognostic factors are increasingly used to guide treatment intensity. High-dose chemotherapy has become an accepted treatment option, in particular in patients with poor risk factors at relapse. The outcome of patients with multiply relapsed or cisplatin-refractory disease remains particularly poor. Treatment of relapsed patients requires a close cooperation of medical oncologists, urologists, surgeons and radiation oncologists with extensive experience in this disease.

Written by
Kollmannsberger C, Honecker F, Bokemeyer C.

Reference
Expert Opin Pharmacother. 2008 Sep;9(13):2259-72.
doi:10.1517/14656566.9.13.2259

PubMed Abstract
PMID:18710351

UroToday.com Testicular Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!